Company
Headquarters: Tokushima, Japan
Employees: 11
¥7.22 Billion
JPY as of Jan. 1, 2024
US$51.3 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323 to treat lung cancer; DFP-17729, DFP-11207, and DFP-14927 for the treatment of solid tumors; and DFP-10825 for peritoneal metastasis. The company was founded in 2010 and is headquartered in Tokushima, Japan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Delta-Fly Pharma, Inc. has the following listings and related stock indices.
Stock: JPX: 4598 wb_incandescent